Weight loss medications such as Ozempic, Mounjaro, and Wegovy are associated with a significantly higher risk of hair loss, according to a new study of 50,000 patient records. Researchers from the University of Pennsylvania found that people prescribed semaglutide or tirzepatide had a 37% to 68% higher risk of alopecia compared with those taking other diabetes drugs, even after adjusting for factors like age and weight. The findings, published in the BMJ, confirm what many patients have reported as 'Ozempic hair' – a side effect that, while rarely physically harmful, can have serious psychological impacts.
Study details and reported cases
The study analyzed patient records to compare rates of hair loss among users of GLP-1 inhibitors (semaglutide and tirzepatide) versus other diabetes medications. The increased risk persisted even when controlling for weight loss, suggesting a potential direct effect of the drugs. This is not a new issue; hair loss is listed as 'common' on manufacturer patient information leaflets.
In the UK alone, the Medicines and Healthcare Products Regulatory Agency (MHRA) has received nearly 400 reports of hair loss related to tirzepatide and 148 linked to semaglutide so far this year. The researchers note that while the condition is 'fairly rare overall' and 'does not typically result in physical harm,' it 'may have significant psychosocial consequences, affecting self-esteem, quality of life, and adherence to treatment.'
Why do weight loss jabs cause hair loss?
Experts say the medication itself is not the direct cause. 'Hair loss has been reported in around 3% of adults taking Wegovy during licensing trials, although the likelihood appears to increase in people who experience more substantial weight loss,' said Dr Abdulaziz Balwi, lead hair surgeon at Elithair. 'Importantly, this side effect is not thought to be caused by the medication itself, but rather by the rapid weight loss it can trigger, which may lead to a condition known as telogen effluvium.'
Telogen effluvium is a temporary condition where stress or a change to the body pushes a large number of hair follicles into the shedding phase. Normally, only 15% of scalp hair is in this phase, but in affected individuals it can rise to 30% or more. Dr Balwi explains that shedding typically begins 'around two to four months after starting treatment or following an increase in dosage.' Common signs include extra hair on pillows, in brushes, or in shower drains, along with diffuse thinning rather than distinct bald patches. Women may first notice a thinner ponytail or wider parting.
Is the hair loss permanent?
For most people, the condition is temporary. 'In most cases, it is temporary, and hair growth typically resumes once weight stabilises and nutritional intake is balanced,' said Dr Babak Ashrafi of Superdrug Online Doctor. However, for those with more severe or persistent shedding, specialist treatments are available. Dr Munir Somji, founder of DrMediSpa, says he is seeing more patients with this issue and recommends a combination of Croma PRP and PolyPhil Polynucleotides, which 'nourish the scalp, stimulate dormant follicles, and reboot the hair growth cycle.'
How to reduce the risk of 'Ozempic hair'
While there is no guaranteed prevention, reducing nutritional and metabolic stress can help. Dr Balwi advises:
- Being gentle with hair: limit heat styling, avoid tight hairstyles, and use a soft brush.
- Aiming for 1.2 to 1.6g of protein per kilogram of body weight daily, spread across meals, with protein shakes as a convenient option.
- Checking iron levels before starting treatment and every three to six months afterwards, as deficiency can contribute to hair loss.
- Taking supplements like zinc, vitamin D, or B12 only if a deficiency is confirmed, 'not on a hunch.'
- Following the recommended 16-week dose escalation schedule, aiming for gradual weight loss of 0.5kg to 1kg per week.
These steps can help mitigate the risk and ensure that weight loss journeys do not come at the cost of hair health.
